I am looking at the "Fiscal Summary" page in the "Market Snapshot" done by Shaw Stockbroking for the ASX, found at the ASX site. I see that the Shaw report is projecting a big increase in operating revenues for Benitec from 1.2 million in 2015 to 60.1 million in 2016. I contacted Shaw and Carl Stubbings to shed some light on this projection and I didn't hear back any relevant information from either one of them. You see to know a lot about Benitec so have you seen the market snapshot and do you know what is the cause of that projected increase. I am concerned they are going to do further dilution but if they sell additional shares that would not be operating revenue increase would it? Just wondering why no one seems to have an answer.
I went to the link and just saw that video for he first time so that's a great find. Thanks. They're talking about Ocata, of course, and a lot of potential investors new to the subject should find that video very interesting.
Sentiment: Strong Buy
I see that Colonial Trust Advisors has started a position in Ocata. They have apparently been around for over 100 years and Ocata is joining the company of Microsoft, Coca Cola, PepsiCo, Union Pacific, Walt Disney, and Duke Energy among others. They have about 140 substantial companies in their portfolio according to NASDAQ.
What are you talking about as you drone on? The facts and independent research shows that glyphosate affects health and the genetic modification of plants potentiates horizontal gene transfer both with negative repercussions to health. Why are you babbling on about global warming and speculating on non-confirmable correlations between various beliefs. Jut stick to the facts and maybe you'll begin to realize that human health is more important than quarterly profits.
Search "ISIS.org" and "Deterioration of Public Health"
Not many cops go to work looking to shoot somebody because it's easier for them to get paid just for doing their job and hoping that nothing goes wrong. The lawyer for the Browns described this as case where the kid got killed for stealing cigars, which is a complete fabrication. That's what leads me to believe the cop is telling the truth plus the testimony of the majority of African American witnesses on the grand jury who more than likely would have wanted to indict this cop if he did something wrong.
even if therapies take 5 years to come to market, and I think it may happen before that in europe, investors will be looking ahead and buying shares in anticipation of where the share price will be in 5 years. nobody wants to buy after the horse is already out of the barn, so if you believe ocat will still be around and selling product in 5 years now is the time to buy. when ocat uplists, share price will go up fast because of institutional buying.
Might be referring to Neuralstem and possibly Verastem. They're both getting good results in clinical testing.
Neuralstem "In September, Jonathan D. Glass, MD, NSI-566 ALS site principal investigator at Emory University, presented long-term follow-up data of approximately 1,200 days on the Phase I trial, at the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal. Dr. Glass reported that patients in the final safety cohort received a total of 15 injections of 100,000 cells treatments in both the lumbar and cervical regions of the spinal cord showed significant slowing of the progression of the symptoms of the disease as measured by the ALSFR-S scores. One patient showed functional improvement from pre-treatment baseline, which is maintained to present day. The other two patients are maintaining the same level of functionality as they had at the baseline."
The past 20 years of ACT history is typical of fits and starts getting new technology to point of acceptance and therapeutic relevance. Aapl hung around in the minor leagues for years, too, but for people that bought at the right time, they got high returns. If you buy OCAT going forward, you'll do better than if you bought 15 or 20 years ago, because now there is an increasing awareness of regenerative medicine that can lead to exponential increase in market value. Institutions will start loading up as soon as the technology is proven valid and before the company makes money. You have to make your bet on the Superbowl before it's played.